Romero AJF, García ALA, Lara GAL, Patricia Rivera VP, Ayala MJA

Language: Spanish
References: 16
Page: 367-375
PDF size: 306.30 Kb.

ABSTRACT

Objective: To assess the maternal and perinatal outcome of patients with antiphospholipid syndrome in pregnancy.
Patients and method: A descriptive and retrospective analysis of patients with antiphospholipid syndrome in pregnancy was made from January 2000 to June 2005.
Results: We analyzed 35 patients. Primary and secondary antiphospholipid syndrome occurred in 25 (71%) and 10 (29%) women, respectively. Nine cases were associated with systemic lupus erythematosus and one with scleroderma. Approximately, 48% of women had history of thrombosis, 23% recurrent pregnancy loss, and 15% early onset preeclampsia in previous pregnancies. Twenty-seven patients had positive anticardiolipin antibodies, 6 lupus anticoagulant, and 2 both of them. About 80% of the patients were delivered by cesarean section. There was one spontaneous embryo loss before seven weeks. Eleven (32%) patients had preeclampsia. There were no maternal deaths. All women began treatment since the first trimester of pregnancy. Twenty-three patients (66%) received heparin and low dose aspirin, 8 cases (22%) heparin, low dose aspirin and prednisone, for presenting systemic lupus erythematosus, and the remaining 4 cases (12%) were treated with prednisone and aspirin. Ninety four percent of the cases got a live newborn. There were two neonatal deaths secondary to extreme prematurity and associated with preeclampsia. There was one fetal death related to maternal lupus renal activity. Fifty-eight percent of the newborns were premature. Intrauterine growth restriction was present in 20% of the cases.
Conclusions: Early treatment combined with close maternal-fetal surveillance was associated with a 90% chance of a live birth rate. However, prematurity, preeclampsia and intrauterine growth restriction were common.

REFERENCES

1. Antiphospholipid syndrome. ACOG Practice Bulletin 2005;68:1113-21.

2. Kupferminc M. Thrombophilia and preeclampsia: the evidence so far. Clin Obstet Gynecol 2005;48:407-15.

3. Carp H. Antiphospholipid syndrome. Curr Opin Obstet Gynecol 2004;16:129-35.

4. Branch W, Khamashta M. Antiphospholipid syndrome: obstetric diagnosis, management and controversies. Obstet Gynecol 2003;101:1333-44.

5. Marai I, Tincani M, Balestrieri G, Shoenfeld Y. Anticardiolipin and anti-beta-2-glycoprotein I antibodies. Autoimmunity 2005;38:33-38.

6. Amigo M, Khamashta M. Antiphospholipid (Hughes) syndrome in SLE. Rheum Dis Clin North Am 2000;26:331-48.

7. Nyberg D, Abuhamad A, Ville Y. Ultrasound assessment of abnormal fetal growth. Semin Perinatol 2004;28:3-22.

8. Sibai B. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003;102:181-92.

9. Shehata H, Nelson-Piercy C, Khamashta M. Antiphospholipid syndrome. Rheum Dis Clin North Am 2001;27:643-59.

10. Oshiro B, Silver R, Scott J, Yu H, Branch W. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996;87:489-93.

11. Gharavi A, Pierangeli S, Levy R, Harris E. Mechanisms of pregnancy loss in antiphospholipid syndrome. Clin Obstet Gynecol 2001;44:11-19.

12. Bats A, Lejeune V, Cynober E, Safar E, et al. Antiphospholipid syndrome and second and third trimester fetal death: follow-up in the next pregnancy. Eur J Obstet Gynecol Reprod Biol 2004;114:125-9.

13. Rivas R, Buitrón R, Romero R. Lupus eritematoso sistémico y embarazo. Ginecol Obstet Mex 2003;71:400-8.

14. Kozer E, Shekoufeh N, Costei A, Boskovic I, et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol 2002;187:1623-30.

15. Empson M, Lassere M, Craig J, Scott J. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002;99:135-44.

16. Esplin M. Management of antiphospholipid syndrome during pregnancy. Clin Obstet Gynecol 2001;44:20-28